UA122043U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography. MTHFR C677T gene polymorphism, thrombomodulin content, folic acid, pyridinoline, homocysteine and 677-TT homozygous carrier, thrombomodulin levels> 5 ng / ml, folic acid, <6 ml / ml, folic acid, <6 ml / ml, folic acid <6 / ml, additionally determined in serum homocysteine> 20 μmol / l is diagnosed with atherosclerosis.

Description

A useful model belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (AN Okorokov.

Diagnosis of diseases of internal organs. - Vol. 6 - pp. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis at the beginning of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, together with a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEK C677T), the content of thrombomodulin, folic acid, pyridinoline, homocysteine is determined in the patient's blood serum. With homozygous carrier 677-TT, levels of thrombomodulin » 5 ng/ml, folic acid «x b ng/ml, pyridinoline » 8 ng/ml, homocysteine » 20 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. The polymorphism of the MTNEK C677T gene is determined in the patient's blood serum. The content of thrombomodulin, folic acid, pyridinoline, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 677-1T, levels of thrombomodulin » 5 ng/ml, folic acid » 6 ng/ml, pyridinoline » 8 ng/ml, homocysteine » 20 μmol/l, the development of atherosclerosis is diagnosed.

A specific example of using the method.

Patient N., 48 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. There are no signs of atherosclerosis. The MTNEK gene polymorphism was determined in blood serum

C677T. The content of thrombomodulin, folic acid, pyridinoline, homocysteine was determined by immunoenzymatic method. Homozygous carrier 677-1T was established. Levels of thrombomodulin - 9.6 ng/ml, folic acid - 3.7 ng/ml, pyridinoline - 15 ng/ml, homocysteine - 33 μmol/l.

The development of atherosclerosis was diagnosed. Arteriographic signs of atherosclerosis were established only after 13 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages of the process.

Claims (1)

USEFUL MODEL FORMULA A method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by which additionally determine in blood serum the polymorphism of the MTNEV gene Сб677Т, the content of thrombomodulin, folic acid, pyridinoline, homocysteine and in the case of homozygous carrier 677-Т1Т, levels of thrombomodulin »5 ng/ml, folic acid «6 ng/ml, pyridinoline »8 ng/ml , homocysteine 220 μmol/l diagnoses the development of atherosclerosis.